Zai Lab Secures EMA Orphan Drug Designation for Zocilurtatug Pelitecan in Pulmonary Neuroendocrine Carcinomas — Zai Lab Limited

Event summary

EMA granted Orphan Drug Designation to Zai Lab's zocilurtatug pelitecan (zoci) for pulmonary neuroendocrine carcinomas (NECs).
Designation follows positive opinion from EMA’s Committee for Orphan Medicinal Products (COMP).
Zoci targets DLL3, a validated therapeutic target overexpressed in neuroendocrine carcinomas like SCLC.
EMA’s ODD provides regulatory incentives, including potential market exclusivity and reduced development fees.
Zai Lab plans three registration-enabling studies for zoci by the end of 2026.

The big picture

Zai Lab’s EMA Orphan Drug Designation for zoci underscores the critical unmet need for effective treatments in pulmonary neuroendocrine carcinomas, particularly aggressive forms like small cell lung cancer (SCLC). This designation aligns with broader industry trends toward targeted therapies and antibody-drug conjugates (ADCs), positioning Zai Lab to potentially disrupt the oncology market with a differentiated therapeutic approach. The strategic significance lies in zoci’s potential to become a global standard of care, supported by compelling clinical data and regulatory incentives.

What we're watching

Clinical Development: The pace at which Zai Lab advances its three registration-enabling studies for zoci will determine its potential global oncology launch timeline.
Regulatory Strategy: How Zai Lab leverages the EMA’s Orphan Drug Designation incentives to streamline clinical development and accelerate approval.
Market Positioning: Whether zoci can establish itself as a first-in-class therapy for pulmonary neuroendocrine carcinomas, given its potential best-in-class safety profile and efficacy.